Citius Pharmaceuticals (NASDAQ: CTXR) grows LYMPHIR sales but posts $49M loss
Rhea-AI Filing Summary
Citius Pharmaceuticals, Inc. reported fiscal third quarter 2026 results centered on the launch of LYMPHIR, its targeted immunotherapy commercialized through majority-owned Citius Oncology. Revenue was $1.49 million for the quarter and $7.11 million for the first nine months of fiscal 2026, all from LYMPHIR commercial sales.
Cash and cash equivalents were $17.0 million as of June 30, 2026. The company recorded a quarterly net loss attributable to common stockholders of $8.86 million and a nine‑month net loss of $38.3 million, with a nine‑month operating loss of $52.9 million and net cash used in operating activities of $23.0 million. Inventory totaled $22.6 million.
Management highlighted growing LYMPHIR adoption, including availability at 44 leading oncology centers and nationwide deployment of an expanded 29‑person commercial and medical affairs organization. Early‑stage data in combination with pembrolizumab and as a pre‑CAR‑T therapy showed encouraging response rates, and late‑stage programs Mino‑Lok and Halo‑Lido have completed pivotal and Phase 2b trials, respectively.
Positive
- $7.1 million in revenue in the first nine months of fiscal 2026 from LYMPHIR marks the company’s transition from no prior-period product revenue to an initial commercial stream.
- LYMPHIR adoption is broadening, with availability at 44 academic oncology centers, NCCN institutions and community infusion centers, and an expanded 29‑person commercial and medical affairs team deployed nationwide.
- Early clinical data for LYMPHIR combinations are promising, including an 86% objective response rate and 57% complete response rate as pre‑CAR‑T therapy in high‑risk relapsed or refractory DLBCL with no dose‑limiting toxicities observed.
- Late‑stage pipeline assets are advancing: Mino‑Lok’s pivotal Phase 3 trial met its primary and secondary endpoints, and a Phase 2b trial for Halo‑Lido was completed in 2023, with active regulatory discussions underway.
Negative
- The company reported a sizeable nine‑month net loss of $49.4 million and an operating loss of $52.9 million, indicating expenses significantly exceed current LYMPHIR revenues.
- Net cash used in operating activities was $23.0 million for the first nine months of fiscal 2026, and the company paid $7.0 million in license fees, highlighting substantial cash burn.
- Forward‑looking statements reference “our need for substantial additional funds” and the ability to finance operations “for at least the next 12 months as a going concern,” signaling going‑concern risk.
- Risk disclosures include the need to “regain compliance with Nasdaq’s continued listing standards” and ongoing dependence on capital markets, commercialization success, and third‑party partners.
Filing Explained
By June 30, 2026, common shares had risen from 18,067,744 to 27,452,570, reducing each unchanged holder’s ownership percentage absent offsets.
This Form 8-K reports the company’s fiscal third-quarter 2026 results under Item 2.02, with the press release furnished as Exhibit 99.1; the reporting event is complete.
At
The nine-month cash-flow statement records
The reported weighted-average share count includes pre-funded warrants; under the supplied definition, those warrants convert into shares when exercised.
The filing’s forward-looking section identifies the need for substantial additional funds to support operations for at least the next 12 months, along with the ability to raise that money, as a risk.
8-K Event Classification
Key Figures
Key Terms
in-process research and development financial
non-controlling interest financial
deferred financing costs financial
orphan drug designation regulatory
cutanous T-cell lymphoma medical
Earnings Snapshot
FAQ
How much revenue did Citius Pharmaceuticals (CTXR) generate from LYMPHIR in fiscal Q3 2026?
What was Citius Pharmaceuticals’ (CTXR) cash position as of June 30, 2026?
How widely is LYMPHIR distributed according to Citius Pharmaceuticals’ (CTXR) update?
What key clinical data for LYMPHIR did Citius Pharmaceuticals (CTXR) highlight?
What are the main late-stage pipeline programs at Citius Pharmaceuticals (CTXR)?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
| (Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 14, 2026, Citius Pharmaceuticals, Inc. issued a press release announcing its results of operations for the third quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release, dated August 14, 2026. | |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 14, 2026 | CITIUS PHARMACEUTICALS, INC. | |
| By: | /s/ Leonard Mazur | |
| Leonard Mazur | ||
| Chairman and Chief Executive Officer | ||
2
Exhibit 99.1
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR®
$17 million in cash and cash equivalents as of June 30, 2026
Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide
CRANFORD, N.J., August 14, 2026 – Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).
“The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR’s differentiated clinical profile,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology.
“Following the quarter end, we completed the nationwide deployment of Citius Oncology’s expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR’s success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures,” added Mazur.
“We also continued to advance LYMPHIR’s longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings, showed an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR’s potential beyond cutaneous T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR,” concluded Mazur.
Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments
| ● | Continued commercial momentum for LYMPHIR, with availability in 44 institutions, including academic oncology centers, leading National Comprehensive Cancer Network (NCCN) institutions and community infusion centers; |
| ● | Increased the number of new institutions ordering LYMPHIR by 80% and grew institutional vial orders from wholesalers by 31%; |
| ● | Drove continued institutional demand growth in July, with 383 vials ordered by institutions from wholesalers, the largest vial order month to date; |
| ● | Secured near universal payer coverage, with no reimbursement denials or preauthorization barriers reported to date; |
| ● | Expanded Citius Oncology’s commercial organization by 21 commercial field-based professionals and added eight medical science liaisons, with nationwide deployment completed in August 2026 through EVERSANA, the Company’s exclusive commercialization partner; |
| ● | Advanced Phase 1 investigator-initiated trials: |
| ○ | Data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting evaluating LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies: |
| - | 24% overall response rate (ORR) and a 48% clinical benefit rate, and |
| - | median progression-free survival of 20.5 months among patients achieving clinical benefit; |
| ○ | Data were presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings evaluating LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL): |
| - | 86% ORR, including 57% complete response (CR) and 29% partial response (PR), |
| - | LYMPHIR was well-tolerated with no dose-limiting toxicities observed; |
| ● | Closed a registered direct offering in April 2026 for net proceeds of approximately $4.5 million; |
| ● | Received approximately $9.7 million in net proceeds from the exercise of certain warrants and funded $10.0 million under the first tranche of a Citius Oncology senior secured term loan facility of up to $25.0 million; and, |
| ● | Citius Oncology appointed Jonathan Peri, Ph.D., J.D., as an independent director, effective August 10, 2026, expanding the board to nine members. |
2
Fiscal Third Quarter 2026 Financial Highlights and Subsequent Developments
| ● | Cash and cash equivalents of $17.0 million as of June 30, 2026; |
| ● | Revenues of $1.5 million for the three months ended June 30, 2026, compared with no revenue for the three months ended June 30, 2025; and $7.1 million for the nine months ended June 30, 2026, compared with no revenue for the nine months ended June 30, 2025; |
| ● | Gross profit of $1.0 million for the three months ended June 30, 2026, representing a gross margin of approximately 67%, and $5.5 million for the nine months ended June 30, 2026, representing a gross margin of approximately 77%; |
| ● | Research and development expenses of $1.1 million for the three months ended June 30, 2026, compared with $1.6 million for the three months ended June 30, 2025; and $4.3 million for the nine months ended June 30, 2026, compared with $7.5 million for the nine months ended June 30, 2025; |
| ● | General and administrative expenses of $6.1 million for the three months ended June 30, 2026, compared with $4.4 million for the three months ended June 30, 2025. General and administrative expenses were $38.3 million for the nine months ended June 30, 2026, compared with $14.6 million for the nine months ended June 30, 2025. The nine-month increase primarily reflects a non-recurring $19.7 million contract cancellation charge recognized in March 2026 and increased expenses related to the commercial launch of LYMPHIR; |
| ● | Stock-based compensation expense of $3.8 million for the three months ended June 30, 2026, compared with $2.7 million for the three months ended June 30, 2025; and $11.9 million for the nine months ended June 30, 2026, compared with $7.9 million for the nine months ended June 30, 2025; and, |
| ● | Net loss applicable to common stockholders of $8.9 million, or $(0.34) per share, for the three months ended June 30, 2026, compared with $8.8 million, or $(0.80) per share, for the three months ended June 30, 2025; and $38.3 million, or $(1.64) per share, for the nine months ended June 30, 2026, compared with $29.5 million, or $(3.27) per share, for the nine months ended June 30, 2025. |
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
3
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to regain compliance with Nasdaq’s continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain regulatory approval for and commercialize or enter into strategic partnerships with respect to Mino-Lok and Halo-Lido; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Pharma’s Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and as amended on January 28, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
– Financial Tables Follow –
4
CITIUS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| June 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 17,007,523 | $ | 4,252,290 | ||||
| Accounts receivable, net of allowances | 686,235 | - | ||||||
| Inventory | 22,625,945 | 22,286,693 | ||||||
| Prepaid expenses | 3,011,660 | 1,395,490 | ||||||
| Total Current Assets | 43,331,363 | 27,934,473 | ||||||
| Operating lease right-of-use asset, net | 753,039 | 818,694 | ||||||
| Deposits | 38,062 | 38,062 | ||||||
| In-process research and development, net of accumulated amortization | 88,785,938 | 92,800,000 | ||||||
| Goodwill | 9,346,796 | 9,346,796 | ||||||
| Total Other Assets | 98,170,796 | 102,184,858 | ||||||
| Total Assets | $ | 142,255,198 | $ | 130,938,025 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 8,037,899 | $ | 13,693,692 | ||||
| License payable | 15,650,000 | 22,650,000 | ||||||
| Accrued expenses | 25,913,962 | 4,190,253 | ||||||
| Accrued compensation | 1,871,320 | 3,292,447 | ||||||
| Note payable | - | 1,000,000 | ||||||
| Operating lease liability | 176,170 | 88,348 | ||||||
| Total Current Liabilities | 51,649,351 | 44,914,740 | ||||||
| Deferred tax liability | 7,696,443 | 7,770,760 | ||||||
| Notes payable, net of deferred financing fees | 6,410,161 | - | ||||||
| Operating lease liability – noncurrent | 590,787 | 724,925 | ||||||
| Total Liabilities | 66,346,742 | 53,410,425 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding | - | - | ||||||
| Common stock - $0.001 par value; 250,000,000 shares authorized; 27,452,570 and 18,067,744 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively | 27,452 | 18,068 | ||||||
| Additional paid-in capital | 343,704,577 | 306,336,239 | ||||||
| Accumulated deficit | (277,118,897 | ) | (238,804,129 | ) | ||||
| Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | 66,613,132 | 67,550,178 | ||||||
| Non-controlling interest | 9,295,324 | 9,977,422 | ||||||
| Total Equity | 75,908,456 | 77,527,600 | ||||||
| Total Liabilities and Equity | $ | 142,255,198 | $ | 130,938,025 | ||||
5
CITIUS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | $ | 1,493,788 | $ | — | $ | 7,105,197 | $ | — | ||||||||
| Cost of revenues | (491,843 | ) | — | (1,609,929 | ) | — | ||||||||||
| Gross Profit | 1,001,945 | — | 5,495,268 | — | ||||||||||||
| Operating Expenses | ||||||||||||||||
| Research and development | 1,053,869 | 1,621,325 | 4,287,106 | 7,514,888 | ||||||||||||
| Amortization of in-process research and development | 1,720,312 | — | 4,014,062 | — | ||||||||||||
| General and administrative | 6,149,173 | 4,447,008 | 38,261,001 | 14,626,882 | ||||||||||||
| Stock-based compensation – general and administrative | 3,810,665 | 2,719,674 | 11,879,167 | 7,946,529 | ||||||||||||
| Total Operating Expenses | 12,734,019 | 8,788,007 | 58,441,336 | 30,088,299 | ||||||||||||
| Operating Loss | (11,732,074 | ) | (8,788,007 | ) | (52,946,068 | ) | (30,088,299 | ) | ||||||||
| Other Income (Expense) | ||||||||||||||||
| Interest income | 116,691 | 20,637 | 215,372 | 56,658 | ||||||||||||
| Gain on sale of New Jersey net operating losses | — | — | 3,833,277 | — | ||||||||||||
| Amortization of deferred financing costs | (179,492 | ) | — | (179,492 | ) | — | ||||||||||
| Interest expense | (231,732 | ) | (172,262 | ) | (420,301 | ) | (172,262 | ) | ||||||||
| Total Other Income (Expense), Net | (294,533 | ) | (151,625 | ) | 3,448,856 | (115,604 | ) | |||||||||
| Loss before Income Taxes | (12,026,607 | ) | (8,939,632 | ) | (49,497,212 | ) | (30,203,903 | ) | ||||||||
| Income tax expense (benefit) | (107,347 | ) | 264,240 | (74,317 | ) | 792,720 | ||||||||||
| Net Loss | (11,919,260 | ) | (9,203,872 | ) | (49,422,895 | ) | (30,996,623 | ) | ||||||||
| Net loss attributable to non-controlling interest | 3,056,417 | 414,000 | 11,108,127 | 1,522,000 | ||||||||||||
| Net loss applicable to common stockholders | $ | (8,862,843 | ) | $ | (8,789,872 | ) | $ | (38,314,768 | ) | $ | (29,474,623 | ) | ||||
| Net Loss Per Share - Basic and Diluted | $ | (0.34 | ) | $ | (0.80 | ) | $ | (1.64 | ) | $ | (3.27 | ) | ||||
| Weighted Average Common Shares Outstanding | ||||||||||||||||
| Basic and diluted (includes pre-funded warrants) | 26,169,589 | 11,006,896 | 23,343,869 | 9,020,356 | ||||||||||||
6
CITIUS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED JUNE 30, 2026 AND 2025
(Unaudited)
| 2026 | 2025 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net loss | $ | (49,422,895 | ) | $ | (30,996,623 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation expense | 11,879,167 | 7,946,529 | ||||||
| Issuance of common stock for services | 107,510 | — | ||||||
| Issuance of common stock warrant | 68,597 | — | ||||||
| Amortization of in-process research and development | 4,014,062 | — | ||||||
| Amortization of operating lease right-of-use asset | 65,655 | 152,212 | ||||||
| Amortization of deferred financing costs | 179,492 | — | ||||||
| Deferred income tax expense (benefit) | (74,317 | ) | 792,720 | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net of allowances | (686,235 | ) | — | |||||
| Inventory | (339,252 | ) | (8,940,201 | ) | ||||
| Prepaid expenses | (1,616,170 | ) | 1,386,824 | |||||
| Accounts payable | (5,655,793 | ) | 5,166,831 | |||||
| Accrued expenses | 19,961,209 | 8,506,648 | ||||||
| Accrued compensation | (1,421,127 | ) | 1,481,023 | |||||
| Operating lease liability | (46,316 | ) | (167,911 | ) | ||||
| Net Cash Used In Operating Activities | (22,986,413 | ) | (14,671,948 | ) | ||||
| Cash Flows From Investing Activities: | ||||||||
| License fee payments | (7,000,000 | ) | — | |||||
| Net Cash Used in Investing Activities | (7,000,000 | ) | — | |||||
| Cash Flows From Financing Activities: | ||||||||
| Proceeds from (repayment of) note payable and advance from employee | (1,000,000 | ) | 1,300,000 | |||||
| Repayment of advance from employee | (300,000 | ) | ||||||
| Net proceeds from loan agreement | 9,635,000 | — | ||||||
| Proceeds from exercise of warrants | 9,731,103 | — | ||||||
| Deferred Financing Costs | (892,551 | ) | — | |||||
| Proceeds from sale of Series A preferred stock | — | 100 | ||||||
| Redemption of Series A preferred stock | — | (100 | ) | |||||
| Net proceeds from common stock offerings | 25,268,094 | 16,509,194 | ||||||
| Net Cash Provided By Financing Activities | 42,741,646 | 17,509,194 | ||||||
| Net Change in Cash and Cash Equivalents | 12,755,233 | 2,837,246 | ||||||
| Cash and Cash Equivalents - Beginning of Period | 4,252,290 | 3,251,880 | ||||||
| Cash and Cash Equivalents - End of Period | $ | 17,007,523 | $ | 6,089,126 | ||||
| Supplemental Disclosures of Cash Flow Information and Non-cash Transactions: | ||||||||
| Interest paid | $ | 303,644 | $ | — | ||||
| Operating lease right-of-use asset and liability recorded | $ | — | $ | 786,697 | ||||
| Warrants issued for loan agreement included in deferred financing costs | $ | 749,280 | $ | — | ||||
| Deferred financing costs included in accrued expenses | $ | 1,762,500 | $ | — | ||||
7